Consolidative therapy

Phase 3Small molecule

Consolidative therapy is one of 100 small molecule programs targeting Hypofractionated Radiotherapy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hypofractionated RadiotherapyRecruiting

Non-Small Cell Lung CancerRecruiting

Small Cell Lung CancerNot yet recruiting

Hypofractionated RadiotherapyPhase 3

Recruiting

Non-Small Cell Lung CancerPhase 3

Recruiting

Small Cell Lung CancerPhase 2

Not yet recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

HLX43

Shanghai Henlius Biotech

Phase 3

3 2

Sigvotatug Vedotin

Pfizer

Phase 3

1 3

Consolidative therapy

SSun Yat-sen University

Phase 3

2 4

BPI-7711

BBeta Pharma Shanghai

Phase 3

3 5

Remeron

OOrganon and Co

Preclinical

1 6

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 8

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 9

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—10

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 3Recruiting

Hypofractionated Radiotherapy

NCT06545747

Q4 2028

Phase 3Recruiting

Non-Small Cell Lung Cancer

NCT06734702

Q2 2029

Phase 3Recruiting

Chemoradiotherapy

NCT07052669

Q3 2029

Phase 2Not yet recruiting

Small Cell Lung Cancer

NCT07103408

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer

Recruiting·SSun Yat-sen University·Phase 2·NCT07103395·56 enrolled

Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

Recruiting·SSun Yat-sen University·Phase 3·NCT06734702·497 enrolled

Chemoradiotherapy1 trial

Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC

Recruiting·SSun Yat-sen University·Phase 3·NCT07052669·311 enrolled

Hypofractionated Radiotherapy1 trial

Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI

Recruiting·SSun Yat-sen University·Phase 3·NCT06545747·490 enrolled

Small Cell Lung Cancer1 trial

A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT07103408·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Consolidative therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Consolidative therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Consolidative therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSun Yat-sen University

Consolidative therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q4 2028

Q2 2029

Q3 2029

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

Chemoradiotherapy1 trial

Hypofractionated Radiotherapy1 trial

Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News